IDO1 and hepatocellular carcinoma: Under thermal effects, NLG919 can be precisely released from the delivery system, counteracting IDO-mediated immune suppression and synergizing with NLG919/PI-FVIOs-mediated magnetothermodynamic therapy-induced immunogenic cell death, resulting in effective hepatocellular carcinoma suppression.